SG&A Efficiency Analysis: Comparing Novartis AG and Xenon Pharmaceuticals Inc.

SG&A Efficiency: Novartis vs. Xenon - A Decade of Change

__timestampNovartis AGXenon Pharmaceuticals Inc.
Wednesday, January 1, 2014149930000005496000
Thursday, January 1, 2015142470000009786000
Friday, January 1, 2016141920000006792000
Sunday, January 1, 2017149970000007313000
Monday, January 1, 2018164710000008382000
Tuesday, January 1, 20191436900000010803000
Wednesday, January 1, 20201419700000012944000
Friday, January 1, 20211488600000021967000
Saturday, January 1, 20221425300000032810000
Sunday, January 1, 20231248900000046542000
Monday, January 1, 202412566000000
Loading chart...

Cracking the code

SG&A Efficiency: A Tale of Two Companies

In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Novartis AG and Xenon Pharmaceuticals Inc. have demonstrated contrasting approaches to SG&A efficiency.

Novartis AG: A Steady Giant

From 2014 to 2023, Novartis AG consistently maintained high SG&A expenses, averaging around $14.5 billion annually. Despite a slight decline in 2023, their expenses reflect a robust operational scale, essential for a global leader.

Xenon Pharmaceuticals Inc.: A Rising Star

Conversely, Xenon Pharmaceuticals Inc. showcased a remarkable growth trajectory. Their SG&A expenses surged by over 700% from 2014 to 2023, indicating aggressive expansion and investment in market presence.

Conclusion

This analysis highlights the strategic differences between an established giant and an emerging contender, offering insights into their financial strategies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025